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Vertebrate Host Susceptibility
to Heartland Virus
Angela M. Bosco-Lauth, Amanda E. Calvert, J. Jeffrey Root, Tom Gidlewski, Brian H. Bird,
Richard A. Bowen, Atis Muehlenbachs, Sherif R. Zaki, Aaron C. Brault

Heartland virus (HRTV) is a recently described phlebovirus initially isolated in 2009 from 2 humans who had leukopenia and thrombocytopenia. Serologic assessment of
domestic and wild animal populations near the residence
of 1 of these persons showed high exposure rates to raccoons, white-tailed deer, and horses. To our knowledge,
no laboratory-based assessments of viremic potential of
animals infected with HRTV have been performed. We
experimentally inoculated several vertebrates (raccoons,
goats, chickens, rabbits, hamsters, C57BL/6 mice, and
interferon-α/β/γ receptor–deficient [Ag129]) mice with
this virus. All animals showed immune responses against
HRTV after primary or secondary exposure. However,
neutralizing antibody responses were limited. Only Ag129
mice showed detectable viremia and associated illness
and death, which were dose dependent. Ag129 mice also
showed development of mean peak viral antibody titers >8
log10 PFU/mL, hemorrhagic hepatic lesions, splenomegaly,
and large amounts of HRTV antigen in mononuclear cells
and hematopoietic cells in the spleen.

H

eartland virus (HRTV) is a novel bunyavirus (family Bunyaviridae, genus Phlebovirus) first identified
in the United States in 2 persons with thrombocytopenia/
leukopenia in Missouri in 2009 (1). The virus has subsequently been isolated from nymphal Amblyomma americanum ticks collected at sites adjacent to the residences
of the index case-patients (2). High seroprevalence rates
for HRTV have been reported in northern raccoons (Procyon lotor), white-tailed deer (Odocoileus virginianus),
and horses sampled near the residences of human casepatients (3). Additional serosurveillance in wildlife has
demonstrated wide-ranging antibody prevalence to HRTV
across the geographic host range distribution of A. americanum ticks (4).
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Genetically, HRTV is most closely related to severe
fever with thrombocytopenia syndrome virus (SFTSV) (1),
a tickborne virus in Asia that causes high fever, thrombocytopenia, leukopenia, gastrointestinal disorders, central
nervous system involvement, disseminated intravascular
coagulopathy; and multiorgan dysfunction. Infection with
this virus shows a case-fatality rate of ≈12% in humans
(5,6). Severe disease progression of patients infected with
SFTSV has further been associated with increased cytokine and chemokine responses (7) and increased viremias
throughout the course of disease (6). Infection of rhesus
macaques with SFTSV caused mild human disease syndromes similar to those in humans, including thrombocytopenia, leukopenia, and increased levels of hepatic and
cardiac enzymes (8).
Unlike SFTSV, which has been associated with thousands of cases of symptomatic human disease in China (5)
and South Korea (9), only 8 diagnosed human cases of
HRTV infection have been reported in the United States,
and 1 death in 2013 (10). Of those patients, 7 were from
Missouri and 1 from Tennessee (this patient died), which
indicated the continued presence of the virus over the
course of several years and over a wide geographic range
(11). Similar to that described for SFTSV, patients infected with HRTV commonly have fever, fatigue, anorexia,
thrombocytopenia, leukopenia, and increased levels of hepatic enzymes (11).
With the recent discovery of SFTSV, HRTV, and
other novel phleboviral agents in recent years (12–14), it
is apparent that tickborne phleboviruses have been largely
underrecognized as potential human disease agents. The
vertebrate host range associations for SFTSV have been
poorly described and have not been addressed for HRTV
by experimental animal inoculation studies.
Given the serologic evidence that northern raccoons
are commonly exposed to HRTV across the central and
eastern United States (4) and near the residence of a human
index case-patient (3), we performed experimental inoculations of raccoons with HRTV. In addition, on the basis of
results of goat serosurveillance for SFTSV in China (15)
and experimental infections (16), we performed experimental inoculation of goats with HRTV. We also assessed
animal models (chickens, rabbits, hamsters, and mice) for

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 12, December 2016

Vertebrate Host Susceptibility to Heartland Virus

host competence for HRTV to identify host range restrictions of the virus and establish a potential model for viremic blood feeding for subsequent tick infections.
Materials and Methods
Viruses and Animal Models

We used an isolate of HRTV (Mo4) obtained from serum
of an acutely ill human patient in the fall of 2009 for experimental infections and plaque reduction neutralization
tests (PRNTs). The isolate was passaged once on Vero E6
cells (African green monkey kidney cell line). Lone Star
virus (LSV) strain 2229 was used as a control virus for intraperitoneal and intracranial inoculation of CD-1 mice. All
animal models (including strain, age, inoculation route, and
dose inoculated) assessed for host competence for HRTV
are shown in Table 1. New Zealand white rabbits, chickens,
Syrian golden hamsters, C57BL/6 mice, and CD-1 mice
were obtained from Charles River Laboratories (Wilmington, MA, USA) and housed at the Centers for Disease
Control and Prevention (Fort Collins, CO, USA) in Animal
Biosafety Level 3 (ABSL 3) conditions. Ag129 mice (α/β/γ
receptor knockout) (17) were originally obtained from B
& K Universal (Hull, UK) and bred in house. The receptor
knockout genotype of the Ag129 mouse breeding line was
confirmed by genetic PCR markers generated from tail snip
tissues from 10 mice (Transnetyx, Cordova, TN, USA).
Boer goats were obtained from a private vendor and
housed in the Colorado State University Animal Disease
ABSL 3 Laboratory. Six raccoons were caught in the wild
in Larimer County, Colorado, and housed in a US Department of Agriculture facility for several months before being transferred to the Animal Disease ABSL 3 Laboratory
at Colorado State University for experimental inoculation.
Raccoon serum samples were screened for neutralizing
antibodies against HRTV/phlebovirus as described (3)
and in this report. All animal handling, trapping, and care
was in compliance with approved Institutional Animal

Care and Use Committee protocols under the oversight
of attending veterinarians. At arrival in the laboratory, all
animals were housed for a minimum of 3 days for acclimatization before inoculation.
Experimental Inoculations

We inoculated animals with 100–105 PFU by subcutaneous, intracranial, or intraperitoneal routes (Table 1). Whole
blood was collected from individual hamsters, rabbits,
chickens and goats daily during 1–7 days postinoculation
(dpi), groups of 3 raccoons on alternating days 1–8 dpi,
and 3 groups of 5 or 6 C57BL/6 and Ag129 mice every
third day 1–9 dpi. Ag129 mice were divided into 5 dosage groups of 15 mice (100–104 PFU) (Table 1). At 28 dpi,
animals from all groups (except raccoons) were bled and
then given booster inoculations with 104 PFU of HRTV
and analyzed through 42 dpi, at which point the animals
were bled and euthanized. Terminal blood samples were
obtained from mice by cardiac bleed under deep isoflurane
anesthesia just before euthanasia. Two Ag129 mice (102
PFU dose group) were terminally bled at 4 days postsecondary challenge, and spleens were harvested for production of monoclonal antibodies (MAbs) as described (18).
Raccoons were anesthetized with a ketamine:xylazine
cocktail (15–20 mg/kg:3–4 mg/kg) (3) given by intramuscular inoculation before sampling, and mice and hamsters
were anesthetized in an isoflurane chamber before serum
sampling. Rabbits, chickens, and goats were manually restrained appropriately for sample collection without use of
anesthetics. Whole blood was collected from peripheral
saphenous, cheek, or tail veins (mouse and hamster); ear
(rabbit); or jugular (chicken and raccoon). Samples were
centrifuged, and serum samples were frozen for subsequent virologic or serologic evaluation. Relative neuroinvasive and neurovirulence phenotypes for HRTV were
compared with that for LSV strain 2229 by intraperitoneal
and intracranial inoculation, respectively. Isoflurane-anesthetized suckling (2 days old) and weanling (17 days old)

Table 1. Experimental inoculation of vertebrate hosts with Heartland virus*
Experimental animal model
Strain
No.
Age, d/sex
Mouse
C57BL/6
15
21/ F
Mouse
Ag129
15
21/M and F
Mouse
Ag129
15
21/M and F
Mouse
Ag129
15
21/M and F
Mouse
Ag129
15
21/M and F
Mouse
Ag129
15
21/M and F
Mouse†
CD-1
10
2
Mouse†
CD-1
10
17
Chicken
Leghorn
3
Adult/F
Hamster
Syrian golden
5
21/F
Goat
Boer
2
Adult/M and F
Rabbit
New Zealand white
3
Adult/F
Raccoon
Wild-caught
6
Adult/M and F

Inoculum dose, PFU
104
104
103
102
101
100
103
103
104
104
104
104
104

*Ag129, interferon-// receptor–deficient; ic, intracranial; ip, intraperitoneal; sc, subcutaneous.
†CD-1 mice were also inoculated similarly with Lone Star virus (same dose and route as for Heartland virus).
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Route of inoculation
ip
ip
ip
ip
ip
ip
ic
ip
sc
sc
sc
sc
sc
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CD-1 mice (n = 10) were inoculated with a 20 µL of sterile
phosphate-buffered saline (PBS) suspension of 103 PFU of
either virus. A group inoculated with minimal essential medium was included as an inoculation control for both routes
of inoculation.
Serologic Testing

HRTV neutralizing and total immune reactive antibodies
were quantified by using a 70% PRNT (PRNT70) (18) and
ELISA, respectively. For PRNTs, serum samples were
heat-inactivated at 56°C for 30 min, and 2-fold serially
diluted serum samples were mixed with an equal volume
of virus suspension. Plaques were enumerated through
10 dpi, and 70% neutralization endpoints were calculated
on the basis of comparison with serum negative controls
as described (3).
ELISAs were performed in 96-well microtiter plates
(Immulon 2HB; Thermo Lab Systems, Franklin, MA,
USA). Plate wells were coated with purified virus (0.06 µg/
well) in buffer (50 mmol/L sodium carbonate, 50 mmol/L
sodium bicarbonate, pH 9.6) and incubated at 4°C overnight (18). Plates were washed 5 times with a PBS/0.1%
Tween wash buffer, and nonspecific binding sites were
blocked with Starting Block (Pierce, Dallas, TX, USA)
(100 µL/well). Serum samples were added in serial dilutions in PBS (50 µL/well) and incubated at 37°C for 1 h.
Plates were washed 5 times before addition of the speciesappropriate horseradish peroxidase conjugate (50 µL/well),
diluted 1:5,000 in PBS. After an incubation period of 1 h
at 37°C, plates were washed and enhanced K-Blue TMB
(3,3′,5,5′ tetramethylbenzidine) substrate (Neogen, Lexington, KY, USA) was added to each well (100 µL/well).
The plates were incubated in the dark at room temperature
for 10 min. Optical density (OD) was read on an automatic
plate reader at 450 nm. Endpoints were determined as an
OD reading on duplicate samples that was at least twice
that of the average OD for control serum samples. Titers
were expressed as the geometric mean of the reciprocal of
the endpoints.

Immunohistochemical Analysis

HRTV-inoculated Ag129 mice with signs of disease were
subjected to necropsy. Spleen, liver, and kidney tissues
were removed, fixed in 10% neutral-buffered formalin,
and processed by using routine methods (10). Immunohistochemical analysis using rabbit polyclonal antisera
against HRTV nucleocapsid (N) protein and an immuno-alkaline phosphatase detection system with Fast Red
Chromogen (Biocare Medical, Concord, CA, USA) was
used as described (1).
Results
Viremia, Death, and Clinical Assessment

Serum samples from chickens, raccoons, goats, rabbits, and
hamsters obtained during 1–7 dpi did not show detectable
HRTV viremia (Table 2). Despite the previous finding that
SFTSV replicates to detectable levels in serum and results
in pathologic changes in spleens of immunocompetent
C57BL/6 mice (19), viremia was not detected in any serum
samples from this strain of mice inoculated with HRTV.
No infection-associated deaths or clinical signs of illness
were observed throughout the course of the infection in any
of inoculated animals.
In contrast, 100% of CD-1 mice inoculated intracranially with LSV died within 6 dpi. However, illness or
death were not observed in mice inoculated with minimal
essential medium or HRTV. Similar to intraperitoneally inoculated C57BL/6 mice, intraperitoneally inoculated CD-1
mice showed no signs of illness or death. However, Ag129
mice showed virus dose-dependent death. Deaths were observed in the group inoculated with 104 PFU; the first signs
of illness appeared on 4 dpi and death occurred on 5 dpi
(Figure 1, panel A). Groups inoculated with 103, 102, 101, or
100 PFU had mortality rates of 85%, 83%, 80%, and 20%,
respectively. Average survival time was inversely proportional to the inoculation dosage. Mean ± SD survival time
ranged from 4.1 ± 0.4 d for the 104 PFU dose group to 19.4
± 4.2 d for the 101 PFU dose group (Figure 1, panel A).

Table 2. Viremia and antibody responses of animals experimentally inoculated with Heartland virus*
Inoculum dose, Mean peak
Mean ELISA
ELISA positive,
Mean PRNT70
Animal
PFU
titer†
dpi
titer‡
no. (%)
titer‡
Mouse (C57BL/6)
104
<1.5
42§
4.4 (0.6)
15 (94)
0.7 (0.6)
Chicken
104
<1.5
14
NT
NA
ND
Chicken
104
NA
42§
3.0 (0.2)
3 (100)
ND
Hamster
104
<1.5
42§
4.3 (0.5)
4 (100)
1.3 (0.4)
Goat
105
<1.5
28
NT
NA
1.0
Goat
105
NA
42§
3.0
2 (100)
1.3
4
Rabbit
10
<1.5
14
NT
NA
ND
Rabbit
104
NA
42§
4.1
3 (100)
1.2 (0.2)
Raccoon
104
<1.5
42
NT
NA
0.4 (0.6)

PRNT70
positive, no. (%)
10 (63)
0
0
5 (100)
2 (100)
2 (100)
0
3 (100)
2 (33)

*Bold indicates initial (not given a booster immunization) sampling of a pair of animals that were later given a booster immunization. dpi, day
postinoculation; NA, not assessed; ND, not detected (no titer <1:10 for any animal); NT, not tested; PRNT70, 70% plaque reduction neutralization test.
†Detection limit was 1.5 log10 PFU/mL.
‡log10 reciprocal titer (SD).
§Animals were given booster inoculations with 104 PFU of Heartland virus at 28 dpi.
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Figure 1. Dose response of Heartland virus (HRTV)–infected interferon α/β/γ receptor–deficient (Ag129) mice. Mice of either sex
were inoculated with 104–10° PFU of HRTV/0.1 mL of inoculum. Mice were observed daily for death through day postinoculation 24.
A) Percentage survival. B) Dose-associated HRTV viremias determined by plaque assays on Vero E6 cells. Different groups of 5 mice
inoculated with the same dose of HRTV were bled every third day. Thus, a decrease in viremia was observed for the 102 PFU dose
inoculum group days postinoculation 5 and 6. Error bars indicate SD.

Mean ± SD time of death also showed prolonged survival
rates with lower inoculation doses when survivors were
omitted from the analyses: 4.1 ± 0.4 d (104), 5.1 ± 0.3 d
(103), 7.7 ± 2.2 d (102), 9.1 ± 3.7 d (101), and 9 ± 1.4 d (100)
(Figure 1, panel A). We calculated a 50% lethal dose of 9
PFU by using linear regression analysis of the mortality
rate at various viral dilutions (R2 = 0.84).
Viremia titers were also dose dependent; peak titers
were highest in the 104 PFU group and lowest in the 100
PFU group (Table 3). Onset of viremia in most of the inoculation groups was at 2 dpi or 3 dpi, and the 104 PFU
inoculation group had the highest initial daily viremia titer
at 2 dpi (2.5 ± 0.5 log10 PFU/mL serum) and the highest
mean daily peak viremias by 5 dpi (8 log10 PFU/mL serum)
(Figure 1, panel B). However, 3 of the mice had viremias at
5 dpi >9 log10 PFU/mL serum. Only 5 of 15 Ag129 mice in
the 100 inoculation group had detectable viremias; highest
detectable titer was 4 log10 PFU/mL serum. Clinical signs
in Ag129 mice included hunched back, ruffled fur, mucopurulent ocular discharge, and hematochezia. Mice that had
these signs were euthanized and subjected to necropsy for
gross and histopathologic analysis of lesions.
Serologic Analysis

All animals except raccoons received booster inoculations at 28 dpi with 104 PFU of HRTV. HRTV neutralizing
antibodies were not detected in chickens through 42 dpi
after booster inoculation, but ELISA titers were evident
(3.0 log10) (Table 2). Low, but detectable, PRNT70 titers (1
log10–1.3 log10) were observed in rabbits given booster inoculations; ELISA titers were <4.1 log10. All hamsters given booster inoculations had neutralizing titers (1 log10–1.9

log10) and ELISA titers (4.3 log10). Despite the high HRTV
neutralizing antibody prevalence and magnitude of the immune response identified in the field for raccoons, 0 of 6
experimentally inoculated raccoons had detectable viremia,
and only 2 had PRNT70 titers (1 log10 and 1.3 log10). ELISA
titers for raccoons were not assessed because of a lack of
appropriate species-associated conjugate. The 2 goats had
low (1.3 log10) neutralizing immune responses after booster
inoculation, and ELISA titers of 3.0 log10 were detected.
C57BL/6 mice responded to infection with no detectable
(0.7 log10) titers detected by PRNT and 4.4 log10 titers detected by ELISA (Table 2).
Serologic Response and Challenge of
Surviving Ag129 Mice

Eighteen (24%) of 75 Ag129 mice survived the initial inoculation with HRTV (11 from the 100 PFU group, 3 from
the 101 PFU group, 2 from the 102 PFU group, and 2 from
the 103 PFU group). The 2 surviving Ag129 mice from the
103 PFU group were terminally bled for immune responses
at 21 dpi. One mouse had an ELISA titer of 1:364,500, and
the other mouse had no detectable reactivity (titer <1:500)
(Table 3). The 2 Ag129 mice that survived the 102 PFU
inoculation dose had ELISA titers of 1:121,500 and <1:500
at 28 dpi. These mice were given booster inoculations with
104 PFU of HRTV, and spleens harvested 4 days later (32
dpi) for detection of splenocyte fusions and myeloma cells
for MAb development as described (18). At 32 dpi (4 days
post-HRTV booster inoculation/challenge), neutralizing
responses were detected in both mice (1.9 log10 and 2.5
log10 reciprocal titers), and no serum viremia or virus was
detected in the spleens.
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Table 3. Viremia and antibody responses of interferon-// receptor–deficient mice experimentally inoculated with Heartland virus*
Mean ELISA
ELISA positive,
Mean PRNT70
PRNT70 positive,
Inoculum dose, PFU
dpi
Mean peak titer†
titer
no. (%)
titer‡
no. (%)
104
NA
8 (1.0)
NA
NA


104
NA
NA
NA



103
21
6.6 (1.2)
4.1 (2.0)
1 (50)
NT

102
28
5.3 (2.3)
3.9 (1.7)
1 (50)
NT
NT
2
10
32
NT
2.2 (0.4)
2(100)§


101
28
4.6 (2.1)
3.5 (1.4)
1 (33)
1.5 (0.6)
ND
101
42
NT
1.3 (0.5)
1 (33)


100
28
3.4 (2.2)
2.7 (1.4)
1 (9)
1
1 (9)
100
42
NT
1.5 (0.6)
2 (33)


*Bold indicates initial (not given a booster immunization) sampling of a pair of animals that were later given a booster immunization. dpi, day
postinoculation; NA, not applicable because uniform deaths were observed; ND, not detected; NT, not tested; PRNT 70, 70% plaque reduction
neutralization test; , not assessed for titer.
†Peak titers (log10 PFU/mL of serum) (SD). Detection limit was 1.5 log10 PFU/mL.
‡log10 reciprocal titer (SD).
§Tested at 4 d postchallenge.

Only 1 of the 3 Ag129 mice that survived initial challenge with HRTV at a dose of 101 PFU showed immune
reactivity to HRTV antigen by ELISA (titer 1:121,500)
at 28 dpi. Similarly, 1 of 11 surviving Ag129 mice from
the 100 PFU dose group showed HRTV immune reactivity
(titer 1:1,500) (Table 3) at 28 dpi. An HRTV neutralizing
titer of 1:10 was identified in the 28 dpi serum sample from
the ELISA-positive surviving mouse from the 100 PFU
inoculation group. In addition, the surviving mouse with
the higher ELISA titer from the 101 PFU dose group did
not have a detectable PRNT70 titer, although neutralizing
titers were observed at lower thresholds. These 14 surviving mice were challenged with 104 PFU of HRTV at 28
dpi and observed for an additional 14 days through 42 dpi.
Eight (57%) of the 14 secondarily challenged Ag129 mice
survived through 42 dpi (2/3 in the 101 PFU dose group and
6/11 in the 100 PFU dose group), which indicated a protective immune response. However, only 3 of the 8 (1 in 101
PFU dose group and 2 in 100 PFU dose group) surviving
mice had detectable neutralizing antibodies against HRTV,
and the mean ± PRNT70 titers were only 1.9 and 1.5 ± 0.6
for the 2 dose groups, respectively (Table 3).
Pathologic Analysis

At necropsy, hamsters, chickens, rabbits, raccoons, goats,
and C57BL/6 mice were in good physical condition and
none showed gross pathologic lesions associated with
HRTV infection. In contrast, Ag129 mice had clear signs
of illness (Figure 2, panel A), including hunched posture,
ruffled fur, rectal hemorrhage, weight loss, and conjunctivitis. Euthanized Ag129 mice had grossly enlarged, pale
spleens, hepatic hemorrhage, enlarged gall bladders, and
excess peritoneal fluid (Figure 2, panel B). Hematoxylin
and eosin–stained sections of Ag129 spleen and liver and
tissues showed reactive white pulp (Figure 2, panel C),
abundant apoptotic debris and hepatic sinusoids (Figure
2, panel D), and increased numbers of mononuclear cells.
Immunohistochemical analysis showed abundant HRTV
2074

antigen was observed diffusely within splenic mononuclear
cells (Figure 2, panel C), hepatic sinusoidal (Kupffer) cells
(Figure 2, panel D), and renal interstitial mononuclear cells
(Figure 2, panel E).
Discussion
HRTV is a novel bunyavirus known to cause serious disease in a small number of humans. Serologic surveillance
and isolation from A. americanum tick nymphs suggested
that HRTV circulates in an enzootic cycle and spills over
into humans when they are exposed to infected ticks (2,3).
However, in the animal models we present in this study,
no evidence of replicative infection in any of the wildlife
or outbred animals tested was observed, and viremia, illness, and death could only be induced in type I and type
II interferon-receptor knockout mice. Likewise, although
SFTSV has been found to cause viremia and pathologic
manifestations, such as leukopenia and thrombocytopenia
in C57BL/6 mice, which is consistent with human pathologic changes, these mice did not show any clinical signs
of disease, and evidence of viral replication was limited to
the spleen (19).
However, all interferon α/β receptor knockout mice
(IFNAR −/−) inoculated with SFTSV died within 3–4
dpi and showed marked SFTSV antigen expression and
increased viremia profiles than did wild-type mice of the
same genetic background (19,20), which is consistent with
our results for Ag129 mice experimentally inoculated with
HTRV (20). Furthermore, the protective role of the interferon response has also been demonstrated by depleting
interferon in age-resistant C57BL/6 mice infected with another phlebovirus (Punta Toro virus) (21). These data and
the experimental inoculation data in our study indicate that
the interferon response is critical for controlling pathologic
changes of mice infected with phleboviruses.
Similar to pathologic changes reported for SFTSV infection in C57BL/6 mice (19) and IFNAR knockout mice
(20), viremia and major pathologic changes developed in
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Figure 2. Pathologic changes
associated with infection of
interferon-α/β/γ receptor–
deficient (Ag129) mice with
Heartland virus (HRTV). A)
Mouse showing typical clinical
signs of HRTV infection
(ruffled fur, hunched posture,
and squinting eyes). B)
Dissected mouse showing an
enlarged pale spleen (arrow).
C–E) Hematoxylin and eosin
staining (left panels) and
immunohistochemical staining
(right panels) for HRTV
nucleocapsid protein of spleen
(C), liver (D), and kidney (E)
of Ag129 mice at 5–7 days
postinoculation with 104 PFU
virus. Original magnifications: C,
×100; D, ×50; E, ×100.

Ag129 mice inoculated with HTRV, which is consistent
with platelet depletion and subsequent thrombocytopenia.
Histopathologic analysis showed a tropism for mononuclear cells, as shown by detection of HRTV N protein
in splenic mononuclear cells, Kupffer cells, and interstitial mononuclear cells within the kidney. Future studies
are needed to directly assess the capacity of the Ag129
mouse model to recapitulate leukopenia and thrombocytopenia manifestations observed in human disease progression and the subsequent role of splenic macrophages with
platelet depletion (19).
Nine hydridomas expressing HRTV MAbs derived
from HRTV-inoculated Ag129 splenocyte fusions described in this report have been characterized. All of them
were found to be nonneutralizing and reactive to linear
epitopes of the HRTV N protein (18). These results are
not surprising because phlebovirus N protein is the most
abundant protein in the virion and in virus-infected cells
(22–24). Similarly, most MAbs against SFTSV are also
specific for N protein and nonneutralizing (25,26). Because
the humoral response to N protein occurs early in infection, this protein is used as a diagnostic antigen (22,27–30).
The presence of N protein-targeted humoral responses,

measured by ELISA titers, in C57BL/6 and Ag129 mice
with low neutralizing activity supports the hypothesis that
the N protein could serve as an immunologic decoy. Poor
humoral neutralizing response of infected hosts to another bunyavirus, Crimean-Congo hemorrhagic fever virus
(genus Nairovirus), has been associated with enhanced
strain-specific virulence in humans (31). Crimean-Congo
hemorrhagic fever virus is rapidly cleared in immunocompetent mice, replicates to high titer, and induces pathologic
changes and thrombocytopenia in IFNAR mice, similar to
the disparate results obtained in this experiment between
C57BL/6 and Ag129 mice (22,27–30).
The lack of proper receptors, such as dendritic cell–
specific intercellular adhesion molecule 3–grabbing
nonintegrin (DC-SIGN) on Vero cells, used in neutralization assays could also explain the low neutralization
titers we observed. When compared with cells that were
modified to express DC-SIGN, Mukherjee et al. found
that neutralization titers to dengue virus were found to
be increased (32). DC-SIGN has been shown to serve as
a receptor for attachment and endocytosis in phleboviral
infections, including those with SFTSV, Rift Valley fever virus, and Uukuniemi virus (33,34). The extremely
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low level of detected neutralizing antibodies in Ag129
mice that subsequently survived challenge with 1,000
50% lethal doses of HRTV indicates that neutralizing
antibody assays are not congruent with humoral protection levels or that cell-mediated immune responses afford considerable protection.
The vertebrate host competence studies reported here
also demonstrate the potential host specificity that could
have evolved over long periods concomitant with diversification of HRTV from other phleboviruses. Our findings
do not exclude the potential role of multiple vertebrate
host(s) for maintenance of HRTV; several key animals,
such as horses and white-tailed deer, for which there is
serologic evidence of field exposures and tick associations, have yet to be assessed for HRTV host competence.
Nymphal A. americanum ticks, from which HRTV has
been isolated (2), are known to be catholic feeders, and
white-tailed deer may be a major host for the nymphal
stage of these ticks (35). HRTV could potentially circulate without the need for actual replication in the vertebrate host through direct tick-to-tick transmission while
co-feeding nearby on a vertebrate host, as described for
the orthomyxovirus, Thogoto virus (36).
The role of direct tick transmission of virus to the vertebrate host should be considered because it is related to
modulation of the host innate immune response and the
potential establishment of a permissive environment for
HRTV replication. Previous studies have demonstrated that
salivary transmission of Thogoto virus has potentiated the
antagonism of interferon-induced Mx1 antiviral activity
and resulted in successful transmission of co-feeding ticks
on a mouse strain for which parenteral inoculation was unsuccessful (37). Salivary transmission by ticks could be a
major factor because of immunomodulatory effects of the
saliva (38,39) or differential immune signaling because of
specific lectins incorporated onto viral structural proteins,
which result from growth in arthropod cells (40). This
modulation by salivary components could affect initial
replication in skin dendritic cells and result in subsequent
development of viremias and neutralizing titers in fieldcollected animals. Repeated exposure of attached ticks
salivating virus over prolonged periods could be sufficient
for neutralization titers to be manifested in the absence of
viral replication.
In conclusion, this study provides an assessment of the
relative susceptibility of several vertebrate hosts to parenteral infection with HRTV and a preliminary assessment of
a potential model for HRTV-associated disease pathology
in humans. Ag129 mice could be used as a source for establishing direct tick infection or as a transmission model for
infected A. americanum ticks for subsequent assessment of
these and alternative natural vertebrate host candidates for
HRTV transmission.
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